Abstract

Reactive oxygen species (ROS) are implicated in the aetiology of interstitial lung disease (ILD). We investigated the role of large-scale somatically acquired mutations in mitochondrial DNA (mtDNA) and consecutive respiratory chain dysfunction as a trigger of ROS-formation and lung fibrosis. Mitochondria were analysed in lung biopsies from 30 patients with idiopathic or connective tissue disease (CTD)-related ILD and 13 controls. In 17 patients we had paired biopsies from upper and lower lobes. Control samples were taken from lung cancer resections without interstitial fibrosis. Malondialdehyde, a marker of ROS-formation, was elevated in ILD-biopsies (p = 0.044). The activity of the mitochondrial respiratory chain (cytochrome c-oxidase/succinate dehydrogenase [COX/SDH]-ratio) was depressed in ILD (median = 0.10,) compared with controls (0.12, p < 0.001), as was the expression of mtDNA-encoded COX-subunit-2 protein normalized for the nucleus-encoded COX-subunit-4 (COX2/COX4-ratio; ILD-median = 0.6; controls = 2.2; p < 0.001). Wild-type mtDNA copies were slightly elevated in ILD (p = 0.088). The common mtDNA deletion was only present at low levels in controls (median = 0%) and at high levels in ILD (median = 17%; p < 0.001). In ILD-lungs with paired biopsies, lower lobes contained more malondialdehyde and mtDNA deletions than upper lobes and had lower COX2/COX4-ratios and COX/SDH-ratios (all p < 0.001). Acquired mtDNA-mutations and consecutive respiratory chain dysfunction may both trigger and perpetuate ROS-formation in ILD.

Details

Title
Mitochondrial DNA mutations and respiratory chain dysfunction in idiopathic and connective tissue disease-related lung fibrosis
Author
Jaeger, Veronika K 1 ; Lebrecht Dirk 2 ; Nicholson, Andrew G 3 ; Wells, Athol 4 ; Bhayani Harshil 5 ; Amiq, Gazdhar 6 ; Tamm, Michael 7 ; Venhoff Nils 8 ; Geiser, Thomas 6 ; Walker, Ulrich A 1 

 University Hospital Basel, Department of Rheumatology, Basel, Switzerland (GRID:grid.410567.1) 
 Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Department of Rheumatology and Clinical Immunology, Freiburg, Germany (GRID:grid.410567.1); University of Freiburg, Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9) 
 Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, Department of Histopathology, London, UK (GRID:grid.439338.6); Imperial College, National Heart and Lung Institute, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111) 
 Imperial College, National Heart and Lung Institute, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Interstitial Lung Disease Unit, Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, London, UK (GRID:grid.439338.6) 
 Royal Brompton and Harefield NHS Foundation Trust, London, UK (GRID:grid.421662.5) (ISNI:0000 0000 9216 5443) 
 University Hospital Bern, Department of Pulmonary Medicine, Bern, Switzerland (GRID:grid.411656.1) (ISNI:0000 0004 0479 0855) 
 University Hospital Basel, Department of Pneumology, Basel, Switzerland (GRID:grid.410567.1) 
 Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Department of Rheumatology and Clinical Immunology, Freiburg, Germany (GRID:grid.410567.1) 
Publication year
2019
Publication date
Dec 2019
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2202208961
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.